The key to overcoming barriers to effective prevention and treatment in resource-restricted settings involves cooperation between multiple organisations, including medical societies, patient groups, pharmaceutical companies and regulatory agencies
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care
Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Facilitating an open dialogue with patients, to better understand their needs, makes research efforts more valuable in the long-term
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
Continued collaboration to identify new molecular targets and treatments can build on existing success
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.